NCT06956950 Magnesium Sulfate in Addition to Bupivacaine in Ultrasound-guided Transmuscular Quadratus Lumborum Block for Post-Operative Analgesia After Total Hip Arthroplasty
| NCT ID | NCT06956950 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Tanta University |
| Condition | Pain Score Reduction |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2025-05 |
| Primary Completion | 2025-10-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 70 participants in total. It began in 2025-05 with a primary completion date of 2025-10-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this clinical trial is to evaluate the efficacy of adding magnesium sulfate to bupivacaine in ultrasound-guided transmuscular quadratus lumborum block for postoperative analgesia in adult patients underdoing hip arthroplasty. The main questions it aims to answer are: * Does Magnesium sulphate lower Pain score (VAS) postoperatively. * Does Magnesium sulphate lowerTotal opioid consumption postoperatively. and What side effects do participants have when taking Magnesium sulphate? Researchers will compare Magnesium sulphate to a placebo (a look-alike substance that contains no drug) to see if Magnesium sulphate works to lower pain score. Participants will: * Take with have ultrasound-guided transmuscular quadratus lumborum block after surgery using bupivacaine with Magnesium sulphate or with placebo * Followed up 48 hours postoperatively to monitor pain score or any reported side effect.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years. * American Society of Anesthesiology (ASA) class I-III * Undergoing hip arthroplasty . Exclusion Criteria: * Patient refusal. * Body mass index (BMI) \> 40 Kg/m2. * Allergy to local anesthetics or magnesium sulphate. * coexisting coagulopathy. * Local infection at puncture site. * Severe renal impairment ( eGFR \< 30 ml/min)
Contact & Investigator
Mostafa Mohammad Abdelsattar Elbagoury, MD
PRINCIPAL INVESTIGATOR
lecturer of anesthesia and surgical ICU and pain medicine
Frequently Asked Questions
Who can join the NCT06956950 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pain Score Reduction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06956950 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06956950 currently recruiting?
Yes, NCT06956950 is actively recruiting participants. Contact the research team at mostafa.elbagoury@med.tanta.edu.eg for enrollment information.
Where is the NCT06956950 trial being conducted?
This trial is being conducted at Tanta, Egypt.
Who is sponsoring the NCT06956950 clinical trial?
NCT06956950 is sponsored by Tanta University. The principal investigator is Mostafa Mohammad Abdelsattar Elbagoury, MD at lecturer of anesthesia and surgical ICU and pain medicine. The trial plans to enroll 70 participants.